PropThink: Reason To Own STJ Is Gone; Pressure Remains On The Stock
(Thomson Reuters ONE) -
By David Moskowitz
Shares of St. Jude Medical (NYSE:STJ) fell Thursday after the company announced
negative results from the RESPECT trial, which was expected to support U.S.
approval of the Amplatzer PFO Occluder (PFO) for the prevention of recurrent
cryptogenic stroke. While some analysts concluded that the product may be
approvable because the trial showed a numerical benefit, but not a statistically
significant benefit, the stock is expected to weaken further as the market for
PFO is likely to be much smaller than originally expected given the lackluster
trial results. Other analysts are downgrading the stock. In fact, after several
downgrades with last week's earnings results, this morning Credit Suisse took
its rating on STJ down from Outperform to Neutral.
PFO was supposed to be a key growth driver for STJ and a major reason to own the
stock. Analysts were predicting between half a billion and one billion in sales,
and because this level of sales seems unattainable after the RESPECT results,
the stock is likely to remain weak. In addition to the RESPECT trial failure,
STJ has bigger problems. On Wednesday, the company confirmed the early warning
by CEO Dan Starks on its 3Q earnings call that the FDA had found manufacturing
deficiencies at the company, and issued a Form 483. The 483 cited 11
observations that must be addressed at the company's California manufacturing
facility, and STJ stated that it expects to provide written response to the
agency by November 7th. The form can lead to an official warning letter, but the
FDA has yet to issue this citation and will probably wait for a response from
STJ. However, many analysts expect a warning regardless, due to the CEO's tactic
of letting Wall St. know ahead of time. The facility in question makes pace-
makers and defibrillator devices, and STJ noted that operations and
manufacturing continues at the plant. The risk is that the problems may take
substantial time and resources to resolve, which could cause supply disruptions
and may negatively impact margins due to the costs to fix such problems.
Beyond the two issues noted above, the company continues to battle the negative
press over its cardiac defibrillator leads, called Durata (see PropThink's prior
story) On its earnings call, STJ reported weaker-than-expected sales of this
product line and it appears that the company is losing market share over the
Durata skepticism. With so much risk in the story, and the absence of a clear
growth driver to put STJ back on the path to strong growth, investors are likely
to exit the stock and seek out opportunities that have more upside potential
like Medtronic (NYSE:MDT).
Read this article in its original form here.
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com. To learn
more, follow us on Twitter or visit us at http://www.propthink.com.
Disclaimer:
You should assume that as of the publication date of any report or letter,
PropThink, LLC and persons or entities with whom it has relation ships
(collectively referred to as "PropThink") has a position in all stocks (and/or
options of the stock) covered herein that is consistent with the position set
forth in our research report. Following publication of any report or
letter, PropThink intends to continue transacting in the securities covered
herein, and we may be long, short, or neutral at any time hereafter regardless
of our initial recommendation. To the best of our knowledge and belief, all
information contained herein is accurate and reliable, and has been obtained
from public sources we believe to be accurate and reliable, and not from company
insiders or persons who have a relationship with company insiders. PropThink was
not compensated to publish this article. Our full disclaimer is available
at http://www.propthink.com/disclaimer.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: PropThink via Thomson Reuters ONE
[HUG#1652854]
Unternehmensinformation / Kurzprofil:
Datum: 26.10.2012 - 16:16 Uhr
Sprache: Deutsch
News-ID 196844
Anzahl Zeichen: 5116
contact information:
Town:
New York
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 215 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PropThink: Reason To Own STJ Is Gone; Pressure Remains On The Stock"
steht unter der journalistisch-redaktionellen Verantwortung von
PropThink (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
